Company Appendix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Weebit Nano Ltd (ASX: WBT, Weebit or Company) is pleased to provide this activity report for the quarter ended 30 June 2023 (Q4 FY23), along with the Company’s Appendix 4C cash flow report.

Successfully listed on NASDAQ; expanding operations in the USA; executing on strategy...

MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide). U.S. Launch Update: Full reimbursement in the U.S. to be effective from July 1...

Anatara Lifesciences Limited (ASX:ANR) Monthly Activities Report    Monthly Activities ReportMelbourne, July 28, 2021 AEST (ABN Newswire) - Anatara Lifesciences Limited ( ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company's Appendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said, "Anatara is pleased to have made solid progress in obtaining the appropriate approval and grants for our human and anim...